Literature DB >> 26234635

Progression free survival and functional outcome after surgical resection of intramedullary ependymomas.

Kalil G Abdullah1, Daniel Lubelski2, Jacob Miller3, Michael P Steinmetz4, John H Shin5, Ajit Krishnaney2, Thomas E Mroz2, Edward C Benzel2.   

Abstract

We present a 15 year institutional analysis of the factors affecting progression free survival (PFS) and overall survival (OS) in patients undergoing attempted resection of adult intramedullary spinal cord ependymomas. Intramedullary spinal cord tumors are rare but important clinical entities, and ependymomas are the most commonly encountered intramedullary tumor. In total, 53 adult patients over the span of 15 years were analyzed for OS, PFS, and the effects of plane of dissection (POD) and gross total resection (GTR) on functional and long term outcomes. The mean age was 45 years and median follow-up was 54 months. The follow-up neurological outcome and modified McCormick scale were used to determine the functional outcome. Kaplan-Meier curves were used to calculate progression and survival. The overall ability to achieve GTR was significantly correlated to identification of an intraoperative POD (p<0.001). There was a trend towards increased PFS with the ability to achieve a GTR. There was no significant difference in the pre- and postoperative functional outcome scores. The ability to achieve a GTR is strongly correlated to the identification of a POD in ependymomas. There is a trend towards an increased probability of PFS in intramedullary spinal cord tumors when GTR is achieved. The resection of these tumors is likely to halt, but not reverse, neurological deterioration.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ependymoma; Intramedullary; Oncology; Spine tumor

Mesh:

Year:  2015        PMID: 26234635     DOI: 10.1016/j.jocn.2015.06.017

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

1.  Natural history of intramedullary spinal cord ependymoma in patients preferring nonoperative treatment.

Authors:  Bedjan Behmanesh; Florian Gessler; Stephan Dützmann; Daniel Dubinski; Lioba Imoehl; Volker Seifert; Matthias Setzer; Gerhard Marquardt
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

2.  Clinical Prediction Modeling in Intramedullary Spinal Tumor Surgery.

Authors:  Elie Massaad; Yoon Ha; Ganesh M Shankar; John H Shin
Journal:  Acta Neurochir Suppl       Date:  2022

Review 3.  Prognostic factors for surgically managed intramedullary spinal cord tumours: a single-centre case series.

Authors:  Asfand Baig Mirza; Axumawi Gebreyohanes; James Knight; James Bartram; Amisha Vastani; Dimitrios Kalaitzoglou; Jose Pedro Lavrador; Ahilan Kailaya-Vasan; Eleni Maratos; David Bell; Nick Thomas; Richard Gullan; Irfan Malik; Gordan Grahovac
Journal:  Acta Neurochir (Wien)       Date:  2022-07-13       Impact factor: 2.816

4.  Comparative clinical study on seldom segment with multiple segment intramedullary primary spinal cord tumors.

Authors:  J J Sun; J Yang; J C Xie; Q Chang; C C Ma; M Zheng; H I Liao; T Wang; X D Chen; Y F Han; G Z Lin; T Yu; J Zhang; Y Si
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-10-18

5.  Outcome predictors in the management of intramedullary classic ependymoma: An integrative survival analysis.

Authors:  Yinqing Wang; Ranze Cai; Rui Wang; Chunhua Wang; Chunmei Chen
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

6.  Factors associated with postoperative outcomes in patients with intramedullary Grade II ependymomas: A Systematic review and meta-analysis.

Authors:  Xiang-Yao Sun; Wei Wang; Tong-Tong Zhang; Chao Kong; Si-Yuan Sun; Ma-Chao Guo; Jun-Zhe Ding; Shi-Bao Lu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

7.  Efficacy of Two-Stage Surgery for Spinal Cord Ependymomas.

Authors:  Soichiro Takamiya; Toshitaka Seki; Kazuyoshi Yamazaki; Shunsuke Yano; Kazutoshi Hida
Journal:  Asian Spine J       Date:  2021-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.